The company, which develops incisionless surgical robotic technology, emerged from stealth in October 2025. As it emerged, it brought in $10 million in a Series A financing, bringing its total funding at that point to $20 million. Now, the company said that the total has eclipsed $25 million through financing led by a prominent high-net-worth investment firm, with repeat participation from Draper Associates, Actions Capital (formerly K50 Ventures), and Fong’s Family Foundation.
Along with the funding, Intuitive co-founder Dr. Fred Moll — considered the “father of surgical robotics” — has joined the Petal Surgical board. Moll was a participant in the October financing round.
Petal said the funding and addition of Moll to the board signal its momentum as it advances its new approach to surgery that uses acoustic liquefaction (a form of histotripsy), AI and robotics.
“The companies we back are building technologies that sound futuristic — until they suddenly become foundational,” said Tim Draper, founder of Draper Associates, Draper University, and the Draper Venture Network. “They are grounded in real science and engineering, with transformative applications likely to arrive faster than most people expect. Petal is one of those missions. By making surgery incisionless — no cuts, no heat, no toxicity — the body can heal itself naturally. We’re excited to support a future where healing doesn’t begin with harm and where everyone has dignified access to world-class healthcare.”
More about Petal Surgical and its mission
Petal plans to use its additional funding to accelerate its path toward patients through R&D and talent recruitment.
The company believes its incisionless surgery method could create a new standard of care, making advanced treatments safer, more accessible and less traumatic for patients worldwide. It aims to eliminate cutting, pain, trauma and other typical surgical risks. The company says the body heals itself naturally with no cuts, burns or toxicity.
Histotripsy is a method that uses focused ultrasound waves to destroy tumors and other abnormal tissue. A noteworthy company using the method right now is HistoSonics, which develops a histotripsy platform for treating a range of tumors and other indications.
Petal’s platform works with the body’s natural abilities to heal by creating vapor-filled cavities one at a time. This allows for clear and connected treatment regions with more opportunities to break down tougher tissues.
Image-guided surgery engineer, Prash Chopra, founded the company, along with neurosurgeon Dr. Bowen Jiang, robotic-assisted spine surgery pioneer Dr. Nicholas Theodore, and Rony Abovitz, a founder of Mako Surgical. Mako, a leading orthopedic surgical robot platform, now belongs to Stryker.
“Prash lost his father to surgical complications. That loss became a mission—and that mission became Petal,” said Ryan Bloomer, founder, Actions Capital (formerly K50 Ventures). “From the moment we met him, it was clear he wasn’t building an incremental improvement — he was starting over. Three investments later, we’re more convinced than ever that he is the right person to lead the team that will make incisionless surgery the new standard of care.”
